Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates from the Beijing Medical Products Administration for three products, enhancing its product line in the in vitro diagnostic sector [1] Group 1 - The products that received registration include D-Dimer calibrator, calcitonin assay kit (magnetic microparticle chemiluminescent immunoassay), and mycophenolic acid assay kit (IMPDH II method) [1] - The acquisition of these medical device registration certificates enriches the company's offerings in the biochemical, chemiluminescent, and coagulation subfields of in vitro diagnostics [1]

Core Viewpoint - Company Jiukang Bio (300406.SZ) has received a medical device registration certificate from the Beijing Drug Administration for three products, enhancing its product line in the in vitro diagnostic sector [1] Group 1: Product Registration - The products that received registration include "D-Dimer Calibration Product," "Calcitonin Assay Kit (Magnetic Particle Chemiluminescence Immunoassay)," and "Mycophenolic Acid Assay Kit (IMPDH II Method)" [1] - The acquisition of these medical device registration certificates enriches the company's offerings in the fields of biochemical diagnostics, chemiluminescence, and coagulation [1] Group 2: Impact on Company - The new product registrations are expected to enhance the company's core competitiveness and market expansion capabilities [1] - The developments are anticipated to have a positive impact on the company's future operations [1]

Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates from the Beijing Drug Administration for three products, enhancing its product line in the in vitro diagnostic sector and positively impacting its future operations [1] Group 1: Product Registration - The products that received registration include "D-Dimer Calibration Product," "Calcitonin Assay Kit (Magnetic Microparticle Chemiluminescent Immunoassay)," and "Mycophenolic Acid Assay Kit (IMPDH II Method)" [1] - The acquisition of these medical device registration certificates enriches the company's offerings in the biochemical, chemiluminescent, and coagulation subfields of in vitro diagnostics [1] Group 2: Competitive Advantage - The new product registrations are expected to enhance the company's core competitiveness and market expansion capabilities [1] - The positive impact on the company's future operations is anticipated as a result of these developments [1]